The European Medicines Agency: a possible relationship between the Johnson vaccine and “rare” clots | health | Essential information for better health | DW

The European Medicines Agency: a possible relationship between the Johnson vaccine and “rare” clots | health | Essential information for better health | DW
The European Medicines Agency: a possible relationship between the Johnson vaccine and “rare” clots | health | Essential information for better health | DW

The European Union’s drug regulator said on Friday (October 1, 2021) that there is a possible link between rare cases of deep vein thrombosis and the Johnson & Johnson vaccine to prevent Covid-19, and recommended that the case be included as a side effect of the vaccine.

The European Medicines Agency has also recommended adding thrombocytopenia, a disorder that causes tissue bleeding caused by the body’s accidental attack on platelets, among the side effects that occur at a frequency that has not yet been determined in the J&J and AstraZeneca vaccine information booklet.

The European Medicines Agency’s Committee on Safety and Risks reached that conclusion for the COVID-19 vaccine developed by Johnson & Johnson’s Janssen company in light of a review of new evidence from two studies and data collected while the vaccine is being used in the context of vaccination campaigns.

This warning is different from the extremely rare side effect of coagulopathy with thrombocytopenia, according to Bloomberg News.

Venous thromboembolism was already included in the Janssen vaccine risk management plan for COVID-19, but it was among the safety concerns that would be investigated, based on the higher proportion of venous thromboembolism observed among the vaccinated versus placebo group in the clinical study. Large that was used to leave this vaccine.

The Committee therefore recommends that venous thromboembolism as a rare side effect of Janssen vaccine against COVID-19 be included in the product information, along with a warning to raise awareness among health care workers and persons receiving the vaccine, especially those who may have an increased risk of thromboembolism. Venous.

A.H./K.S. (Reuters, dpa)

  • Different nationalities.. Learn about the most famous licensed vaccines around the world

    Biontech/Pfizer Vaccine

    Developed by German Piontech jointly with American Pfizer. Its effectiveness, according to the latest clinical trials, is 95 percent. It is the first vaccine against corona approved by the World Health Organization. It is based on mRNA technology, and is the most widely used vaccine in the Western world, but it has been criticized for the difficulty of storing it, as it needs to minus 70 degrees Celsius to maintain its effectiveness.

  • Different nationalities.. Learn about the most famous licensed vaccines around the world

    Moderna

    The second vaccine to be licensed by the European Union after Pfizer/Biontech. Developed by the American company Moderna in cooperation with the US National Institutes of Health for Infectious Diseases. Its effectiveness has reached 95 percent. It adopts almost the same technology (mRNA), but its storage conditions are less stringent and it needs 20 degrees below zero. Despite this, the quantities of its distribution in the world remained less than the first vaccine, which may be explained by its price of $ 33 per dose, unlike the second vaccine of $ 20.

  • Different nationalities.. Learn about the most famous licensed vaccines around the world

    Sputnik V

    It is the first vaccine in the world whose developers announce its effectiveness against Corona, even though it had not yet passed the third stage. It was developed by the Russian State Aesthetic Institute, and its effectiveness reaches 92 percent, according to Russian figures, but with Western scientific hesitation due to the lack of published data on it. It was imported by several countries, including Hungary, Algeria, Serbia and the UAE. It is easy to transport and cheap ($10) and uses adenovirus (or adenovirus) vector technology.

  • Different nationalities.. Learn about the most famous licensed vaccines around the world

    AstraZeneca/Oxford

    The second vaccine authorized by the World Health Organization and the third for the European Union. The cheapest vaccines, but also the least effective (70 percent), and many countries questioned its effectiveness against the elderly, as well as against mutated versions. Developed by the British-Swedish company AstraZeneca in cooperation with the University of Oxford. It was imported by several countries after the contribution of the Serum Institute of India to its production. It is easy to transport and store and it also uses glandular conveyor technology.

  • Different nationalities.. Learn about the most famous licensed vaccines around the world

    Sinopharm

    Developed by China’s state-owned Sinopharm with Beijing Institute of Biological Products. It was first introduced by the UAE before China licensed it, and then it was imported by several countries, including Morocco, Jordan and Egypt. Its effectiveness rate, according to its manufacturers, reached 79 percent, but the scientific data is not published properly. It uses the inactivated virus injection technique, and the biggest mystery surrounding it is its price, as several reports stated that the dose is not less than $ 30, while others mentioned a lower or higher price.

  • Different nationalities.. Learn about the most famous licensed vaccines around the world

    Coronavac

    It was produced by the Chinese company Sinovac, but licensing it in China took longer. Its effectiveness is controversial, as tests in Brazil showed that it did not exceed 51 percent, but other tests in Turkey, which was among the first to license it, raised the effectiveness to 91 percent. He uses the same technology as the Sinopharma vaccine, and many questions surround him due to the lack of data, especially its price, which has not been reported, although reports have estimated it at ten dollars.

  • Different nationalities.. Learn about the most famous licensed vaccines around the world

    Johnson & Johnson

    It was developed by the American company “Johnson & Johnson”, and South Africa began using it, although it was not licensed in the United States or Europe, after it was found that it was able to confront the mutated version, contrary to what was shown by first experiments. Its effectiveness is estimated at 66 percent globally and 72 in America. It is distinguished from others that it is from a single dose, which strengthens its chances of spreading even more. It uses adenovirus vector technology, and is easy to store.

Source

European Medicines Agency relationship Johnson vaccine rare clots health Essential information health

 
For Latest Updates Follow us on Google News
 

PREV "We have no green idea": Why not tell the public how much the airport in Hadera will cost? – TheMarker
NEXT A member of the Judicial Selection Committee demands to meet with candidates, animals oppose